View printer-friendly version
« Back
September 05, 2007 1:55 p.m.
Teva Receives Favorable Court Decision Regarding Generic Famvir® Tablets

Jerusalem, Israel, September 5, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) Announced today that further to its press release dated August 24, 2007, the U.S. District Court For the District of New Jersey has denied a motion filed by Novartis for a preliminary Injunction related to Teva's Famciclovir Tablets, AB-rated to Novartis' Famvir®.

Teva's Abbreviated New Drug Application (ANDA) to market its Famciclovir Tablets, 125 mg, 250 mg and 500 mg has already been granted final approval by the U.S. Food and Drug Administration (FDA). The brand product had annual sales of approximately $200 million in The United States for the twelve months ended June 30, 2007, based on IMS sales data. As the First company to file an ANDA containing a paragraph IV certification for this product, Teva Has been awarded a 180-day period of marketing exclusivity, which will begin to run from the Date of first commercial marketing.

Teva is currently involved in patent litigation with Novartis concerning this product. A trial date Has not been set.



Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Tevas future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to accurately predict future market conditions including pricing and margins with regard to sales of the generic version of Protonix®, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir® and Protonix®, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Tevas ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Tevas Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.